TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stance Time Symmetry Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment Emergent Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Significant ECG Findings at Any Time During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Delirium-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission rate (CRR)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Post traumatic stress disorder check list (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Standardized Uptake Value Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pin Site Infection Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: T cells response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Airway response to methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decrease of pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of HPV specific IgG in FV urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence or absence of spectroscopic pattern signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of penetration of vaginally-derived biologic analytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of DNA sequences of SRY and TSPY4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of amelogenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in dimensions, weight, biologic or chemical composition of IVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of BK Viruria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rescue analgesic requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HBsAg loss/seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ultrasound lung comets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified Medical Research Council Dyspnea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Visual analog scale to assess the pain severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: The Short Physical Performance Battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale to assess the fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in readiness to change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 1 year follow-up mortality
Endpoint domain: Mortality/survival
Primary endpoint: Presence of Postoperative Delirium
Endpoint domain: Adverse events/effects
Primary endpoint: EEG spectral power in theta band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interval of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from M protein content in plasma at Week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Blood routine in plasma at Week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from liver and kidney function at Week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subject-reported adherence to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of obesity hypoventilation syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary Effectiveness Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dose of Analgesic Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Perceived Treatment Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Intention to Use Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in ipsilateral leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with CD4 count below 300/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 18F-FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled Breath Condensate hydrogen peroxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of postoperative pethidine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient maximum walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of non-sustained ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed P. falciparum and P. vivax malaria parasite incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PCR-based P. falciparum and P. vivax parasite prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of CMPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Clinical Assessment of Balance (ECAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Strength Assessment (FSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six and One-minute Walk Test (6MWT, 1MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival based on timing of completion radical cholecystectomy
Endpoint domain: Mortality/survival
Primary endpoint: Hypoxia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked in the 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating of perceived exertion (RPE) in the 6 minute walk test
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rating of dyspnoea during the six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resolution of Hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in baseline-adjusted pancreatic beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in baseline-adjusted weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Status of frozen tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Control Questionnaire (ACQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Structured Assessment of Ultrasound Skills (OSAUS)-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-Diabetes Indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in RNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in telomerase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurohormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Expression levels of CXCR4, CD47, and pS6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High grade conduction disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Usability of the Inflammacheck device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance of the device in collecting urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Satisfaction in Device Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healthcare provider (HCP) satisfaction in device use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of timolol serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of radiation used in thyroid gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global attrition rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean intact parathyroid hormone (PTH) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the plasma Concentration versus time curve (AUCt) of Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid Marker Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory Marker Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evolution of fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evolution of FIBTEM A5®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Control of phosphatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chemotherapy side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Neo-intimal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Occurrence of JRA/JIA Disease Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall incidence of MDR Gram negative bacteria isolations
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of MDR Gram negative bacteria acquired
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of MDR Gram negative bacteria isolated prior to ECMO connection
Endpoint domain: Adverse events/effects
Primary endpoint: sedation length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilator alarm rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Berg Balance Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruit or vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gut microbiota composition change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Surface Micro Hardness Recovery (% SMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antro-pyloro-duodenal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 30-day unplanned readmission or death
Endpoint domain: Mortality/survival
Primary endpoint: Resonance frequency analysis (ISQ) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraindividual Hemoglobin (Hgb) variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived risk for falls
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence to minimize falls
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to call for assistance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean change in bone mineral density (BMD) (lumbar spine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in BMD (femoral neck)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in BMD (total hip)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change in BMD (forearm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of motricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive Care Unit admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in the maximum plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum level of 25-hydroxycholecalciferol (25(OH)D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in carotenoid appearance in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease of Testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in mean pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous Thrombin Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Family satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in the dimensions of measurable lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional improvement in measurable indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations of patient quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sustained Virological Response (SVR) at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary Tumor Necrosis Factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Employment status
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in Hepatic Steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Estimated Body Weight (EBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of IGG for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rebleeding rate within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least 2-step Decrease in Vitreous Haze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned readmissions within 30 days of discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of outpatient visit with primary care provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Luteinizing hormone pulse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anal pressure pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epigenetic and transcriptome changes in debrided tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound specific genetic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify specific SEEBIN factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pittsburgh Sleep Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Karolinska Sleep Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Caffeine Beverage Consumption
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in depressive symptoms severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline White blood counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Index Participants Who Requested Test Kits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Return Kits for Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reliability of SRQ-T questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Post-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Annualized rate of severe infections
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized rate of moderate and severe bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II dose of GX15-070MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of DLTs of GX15-070MS
Endpoint domain: Adverse events/effects
Primary endpoint: PK/PD response to GX15-070MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNAP-IV teacher form score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants experiencing an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Multiple Choice Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade IV adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: All-cause Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Investigator's global assessment of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function assessed by hepatocyte fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects on glucose, insulin, glucagon, and GH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacodynamic effects on glucose, insulin, IGF-1, IGF-BP1, and IGF-BP3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Effects on TSH, ACTH, Cortisol, PRL, LH, and FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resolution of chronic LE symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prostate specific antigen complete response (PSA-CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With HIV-1 RNA Viral Load <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of peripheral endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of pain by pain measurement score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Trichotillomania Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Salvage index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Neurofilament Light Chain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GFAP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fractional Synthetic Rate of Mixed Muscle Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes